ArticleMedical science monitor : international medical journal of experimental and clinical research2025
Effects of Weight Loss on Insulin Resistance and Liver Health in T2DM and NAFLD Patients.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Efficacy of Orlistat on Cardiometabolic Indices in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A GRADE-Assessed Systematic Review and Meta-Analysis of RCTs.Current therapeutic research, clinical and experimental · 2026Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach.The Kaohsiung journal of medical sciences · 2026Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): New Perspectives on an Evolving Epidemic.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND The rising comorbidity of T2DM and MASLD, driven by insulin resistance (IR), underscores the need for effective interventions. This study evaluated the impact of a 3-month structured lifestyle intervention on hepatic steatosis, IR, and metabolic parameters in patients with T2DM-MASLD. MATERIAL AND METHODS Thirty-seven patients received personalized low-calorie diets and exercise regimens. Hepatic fat was quantified via MRI-PDFF, with biochemical parameters and HOMA-IR assessed at baseline and after intervention. Participants were stratified into compliant (³5% weight loss, n=26) and non-compliant groups (<5%, n=11). RESULTS Both groups had significant reductions in BMI and hepatic fat fraction (p<0.05), with greater improvements in the compliant group. The compliant group had significant improvements in TBIL, AST, ALT, HDL-c, and HOMA-IR (a significant 31.2% reduction in HOMA-IR [p<0.001]). Multivariate analysis revealed that MRI-PDFF explained 42.5% of hepatic fat variability. CONCLUSIONS A 5% weight loss threshold effectively ameliorates hepatic steatosis and IR, reinforcing lifestyle modification as a cornerstone in T2DM-MASLD management. Integration of digital monitoring tools enhances compliance, addressing a critical barrier in real-world implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.